background
quinoxalin
qdno
known
potent
antibacteri
agent
purpos
evalu
bioactiv
exist
animalus
qdno
drug
repres
pathogen
microorgan
repres
drug
quinoxalin
includ
cyadox
mequindox
quinoceton
metabolit
submit
vitro
evalu
antituberculosi
antimycoplasma
antifung
antivir
activ
result
antituberculosi
assay
prototyp
compound
activ
mic
mycobacterium
tuberculosi
bovi
combin
antimicrobi
suscept
test
indic
cyadox
mequindox
quinoceton
combin
rifampicin
addit
effect
tuberculosi
complex
fraction
inhibitori
concentr
index
fic
result
antifung
assay
show
quinoceton
activ
microsporum
cani
mic
antimycoplasma
screen
show
gener
good
activ
quinoceton
mycoplasma
gallisepticum
mycoplasma
hyopneumonia
mic
shown
combin
antimicrobi
suscept
test
cyadox
mequindox
quinoceton
combin
tetracyclin
addit
effect
mycoplasma
gallisepticum
fic
compound
also
submit
antivir
assay
infecti
bursal
diseas
viru
porcin
reproduct
respiratori
syndrom
viru
porcin
parvoviru
classic
swine
fever
viru
result
obtain
show
qdno
metabolit
inhibitori
activ
virus
vitro
conclus
qdno
exhibit
antimicrobi
activ
mycobacteria
mycoplasma
fungi
studi
give
new
insight
applic
qdno
offer
way
promot
healthcar
anim
husbandri
abbrevi
atcc
american
type
cultur
collect
cc
cytotox
concentr
ccu
colour
chang
unit
cfu
colonyform
unit
cpe
cytopath
effect
ct
cycl
threshold
bideoxi
cyadox
cyadox
cyadox
cya
cyadox
ec
effect
concentr
fic
fraction
inhibitori
concentr
index
hclv
hog
cholera
viru
strain
hclv
ibdv
infecti
bursal
diseas
viru
bideoxi
mequindox
carbonyl
reduct
mequindox
carbonyl
reduct
mequindox
maba
microdilut
alamar
blue
assay
meq
mequindox
mic
minimum
inhibitori
concentr
mntc
maximum
noncytotox
concentr
mtt
methylathiazol
tetrazolium
bromid
ppv
porcin
pavroviru
viru
prrsv
porcin
reproduct
respiratori
syndrom
viru
carbonyl
reduct
bideoxi
quinoceton
qct
quinoceton
qdno
quinoxalin
qsar
quantit
structur
activ
relationship
rtqpcr
realtim
quantit
pcr
si
select
index
taacf
tuberculosi
antimicrobi
acquisit
coordin
facil
tcid
tissu
cultur
infect
dose
ti
therapeut
index
microorgan
infect
one
seriou
threat
human
health
anim
product
time
help
antimicrobi
agent
power
weapon
pathogen
howev
misus
antimicrobi
led
develop
drugresist
multidrugresist
mdr
microorgan
resist
bacteria
increas
interv
appear
new
multidrug
resist
speci
happen
short
period
time
mdr
bacteria
increas
worldwid
develop
new
antimicrobi
enhanc
activ
urgent
need
addit
costeffect
approach
evalu
bioactiv
exist
drug
revers
resist
turn
actual
bacteri
profil
quinoxalin
qdno
known
potent
antibacteri
agent
sinc
animalus
qdno
class
synthet
antibacteri
agent
repres
drug
carbadox
olaquindox
mequindox
meq
quinoceton
qct
wide
use
anim
product
antibacteri
growth
promot
previou
studi
demonstr
drug
activ
mani
pathogen
microorgan
includ
escherichia
coli
salmonella
spp
staphylococcu
aureu
pasteurella
multocida
brachyspira
hyodysenteria
etc
cyadox
cya
new
member
qdno
may
substitut
olaquindox
carbadox
low
toxic
broad
antibacteri
spectrum
last
two
decad
mani
paper
publish
synthesi
biolog
activ
assess
larg
number
qdno
deriv
describ
recent
studi
demonstr
qdno
endow
antituberculosi
antivir
antichagas
anticandida
activ
properti
hypox
select
depend
specif
chemic
featur
previou
encourag
result
prompt
us
analyz
biolog
activ
animalus
qdno
purpos
obtain
new
potent
drug
improv
current
chemotherapi
repres
pathogen
microorgan
cya
qct
meq
metabolit
evalu
vitro
antimicrobi
activ
antimicrobi
minimum
inhibitori
concentr
mic
qdno
metabolit
fungi
mycoplasma
mycobacterium
tuberculosi
complex
examin
also
inhibitori
activ
qdno
infecti
bursal
diseas
viru
ibdv
porcin
reproduct
respiratori
syndrom
viru
prrsv
porcin
parvoviru
ppv
evalu
cytopath
effect
cpe
method
methyl
thiazolyl
tetrazolium
mtt
method
sinc
replic
classic
swine
fever
viru
csfv
result
cytopath
effect
vitro
sybr
green
realtim
rtpcr
develop
determin
copi
viru
suspens
compar
growth
curv
whether
qdno
anticsfv
activ
judg
meanwhil
combin
antimicrobi
suscept
test
carri
order
screen
drug
combin
tuberculosi
complex
mycoplasma
provid
scientif
basi
applic
drug
ibdv
prrsv
ppv
csfv
obtain
cvcc
tissu
cultur
infect
dose
tcid
viru
determin
reedmuench
assay
ibdv
prrsv
ppv
dilut
tcid
tcid
tcid
respect
basic
medium
store
futur
use
cell
cell
cell
dilut
cellsml
dulbecco
minimum
essenti
medium
dmem
seed
plate
incub
co
atmospher
cya
bideoxi
cyadox
cyadox
cyadox
qct
carbonyl
reduct
bideoxi
quinoceton
meq
bideoxi
mequindox
carbonyl
reduct
mequindox
carbonyl
reduct
bideoxi
mequindox
carbonyl
reduct
mequindox
tabl
provid
nation
refer
laboratori
veterinari
drug
residu
huazhong
agricultur
univers
wuhan
hubei
china
amphotericin
b
tetracyclin
doxycyclin
ketoconazol
enrofloxacin
danofloxacin
rifampicin
tilmicosin
kitasamycin
purchas
dr
ehrenstorf
augsburg
germani
kanamycin
pyrazinamid
lincomycin
ethambutol
ribavirin
isoniazid
purchas
trc
toront
canada
amikacin
clindamycin
tylosin
purchas
sigma
st
loui
mo
usa
stock
solut
compound
prepar
final
concentr
porcin
mycoplasma
medium
middlebrook
broth
base
medium
mycoplasma
gallisepticum
medium
yeast
pepton
dextros
ypd
medium
purchas
qingdao
hope
biotechnolog
co
ltd
qingdao
shandong
china
medium
hors
serum
bought
gibco
grandisland
ny
usa
dmem
hyclon
beij
china
supplement
heatinactiv
fetal
calf
serum
fc
hyclon
usa
iuml
penicillin
g
streptomycin
use
cell
growth
mainten
medium
trypsin
hyclon
beij
china
prepar
ph
phosphat
buffer
salin
pb
bromid
biosharp
hefei
anhui
china
prepar
pb
solut
steril
millipor
membran
filter
dimethyl
sulfoxid
dmso
purchas
sigma
st
loui
mo
usa
vector
mmlv
rtase
rnasin
compet
cell
sybr
premix
ex
taqtm
ii
tli
rnaseh
plu
purchas
takara
dalian
liaon
china
extract
kit
product
tiangen
biotech
co
ltd
beij
china
trizol
regent
purchas
ambion
shanghai
china
chemic
reagent
commerci
avail
highest
analyt
grade
microdilut
alamar
blue
assay
maba
tuberculosi
complex
activ
qdno
metabolit
well
posit
control
drug
isoniazid
rifampicin
tuberculosi
complex
strain
test
use
maba
briefli
mycobacterium
strain
cultur
middlebrook
broth
supplement
glycerol
oleic
acidalbumindextrosecatalas
sigma
st
loui
mo
usa
logarithm
growth
reach
cfuml
inoculum
mycobacterium
strain
ad
two
fold
serial
dilut
drug
sampl
final
concentr
dmso
assay
less
dilut
also
serv
solvent
control
sampl
assay
triplic
test
carri
steril
flat
bottom
micropl
micropl
incub
day
seal
plastic
co
permeabl
bag
day
incub
mixtur
freshli
prepar
alamar
blue
solut
steril
vv
ad
growthcontrol
well
micropl
incub
h
color
shift
blue
pink
observ
growthcontrol
sampl
alamar
blue
solut
ad
remain
well
micropl
incub
h
welldefin
pink
color
interpret
posit
bacteri
growth
wherea
blue
color
indic
absenc
growth
mic
correspond
concentr
greatest
dilut
drug
sampl
color
shift
blue
pink
observ
antifung
activ
qdno
metabolit
well
posit
control
drug
amphotericin
b
ketoconazol
determin
accord
rodrigueztudela
et
al
briefli
compound
test
macrobroth
serial
dilut
techniqu
aspergillu
fumigatu
candida
albican
cryptococcu
neoforman
candida
tropicali
candida
parapsilosi
trichophyton
rubrum
epidermophyton
floccosum
microsporum
cani
seed
broth
cfuml
prepar
rpmi
medium
ad
serial
dilut
drug
solut
tube
incub
mic
record
h
myceli
fungi
postincub
broth
control
without
fungi
growth
control
fungi
without
drug
solvent
dmso
control
drug
control
test
drug
standard
drug
set
ident
condit
minimum
drug
concentr
tube
appar
growth
organ
observ
repres
mic
compound
mic
determin
qdno
metabolit
posit
control
drug
tylosin
enrofloxacin
mycoplasma
perform
accord
hannan
briefli
microtit
sensititr
plate
contain
stabil
freezedri
antimicrobi
use
three
well
plate
set
antimicrobi
free
growth
control
freshli
thaw
mycoplasma
isol
known
titer
dilut
liquid
medium
number
organ
reach
color
chang
unitsml
dilut
cultur
transfer
well
sensititr
plate
gallisepticum
use
control
strain
test
three
time
order
estim
reproduc
procedur
plate
seal
use
adhes
foil
incub
day
growth
hyopneumonia
observ
daili
color
medium
chang
red
yellow
phenol
red
indic
initi
final
mic
record
initi
mic
defin
lowest
drug
concentr
chang
color
growth
control
turn
yellow
final
mic
defin
lowest
drug
concentr
show
color
chang
day
inocul
fraction
inhibitori
concentr
fic
index
frequent
use
describ
drug
interact
combin
effect
cya
meq
qct
antimycoplasma
drug
tetracyclin
doxycyclin
lincomycin
clindamycin
danofloxacin
enrofloxacin
tylosin
kitasamycin
gallisepticum
studi
use
checkerboard
method
meanwhil
combin
effect
cya
meq
qct
antituberculosi
drug
rifampicin
isoniazid
streptomycin
kanamycin
ethambutol
amikacin
tuberculosi
bovi
studi
way
fic
calcul
accord
equat
fic
fic
fic
b
mic
bmic
b
b
mic
drug
drug
b
combin
mic
mic
b
mic
drug
drug
b
alon
experi
perform
duplic
fic
indic
interpret
follow
synergi
addit
indiffer
antagon
cytotox
qdno
compound
metabolit
measur
mtt
assay
compound
control
drug
ribavirin
serial
dilut
dmem
contain
fc
respect
cell
cell
cell
seed
plate
densiti
cellswel
incub
h
cell
least
confluent
medium
remov
dilut
compound
ribavirin
ad
well
incub
h
medium
discard
mtt
solut
ad
well
plate
incub
h
subsequ
supernat
remov
dmso
ad
well
order
dissolv
formazan
crystal
gentli
shake
plate
min
absorb
read
elisa
micropl
reader
nm
wavelength
nm
refer
wavelength
compound
percentag
cell
viabil
calcul
ab
b
correspond
absorb
control
treat
cell
respect
cytotox
concentr
cc
valu
defin
concentr
compound
reduc
absorb
treat
cell
compar
nontreat
cell
control
maximum
noncytotox
concentr
mntc
calcul
maximum
drug
concentr
retain
cell
viabil
antiprrsv
antippv
antiibdv
activ
qdno
compound
metabolit
evalu
previous
describ
li
et
al
minor
modif
briefli
confluent
monolay
cell
prepar
describ
remov
cultur
medium
mntc
compound
constant
amount
tcid
virus
ad
cell
control
viru
neg
control
ribavirin
posit
control
set
simultan
plate
incub
cpe
viru
neg
control
reach
compar
cell
control
cell
viabil
determin
mtt
method
inhibit
ratio
calcul
base
formula
od
viru
repres
optic
densiti
od
cell
infect
viru
treat
compound
od
c
viru
correspond
od
untreat
virusinfect
cell
od
c
mock
od
untreat
mockinfect
cell
compound
inhibit
ratio
exceed
select
made
serial
dilut
mm
procedur
repeat
describ
effect
concentr
ec
compound
defin
cytoprotect
viru
infect
select
index
si
calcul
ratio
cc
ec
ec
could
calcul
owe
low
inhibit
ratio
cpe
result
count
maximum
inhibit
ratio
virucid
assay
compound
mntc
tcid
virus
mix
interact
h
viruscompound
suspens
ad
cell
plate
incub
co
humidifi
atmospher
plate
observ
microscop
daili
cpe
viru
neg
control
reach
compar
cell
control
mtt
test
perform
describ
infect
inhibit
assay
done
dynam
accord
previou
method
modif
cell
plate
preincub
tcid
virus
h
subsequ
medium
remov
cell
wash
twice
pb
fresh
medium
contain
mntc
compound
ad
plate
incub
co
atmospher
cpe
record
time
interv
h
microscop
cpe
viru
neg
control
reach
compar
cell
control
antiviru
activ
phase
assess
mtt
test
viral
inhibit
ratio
calcul
adsorpt
inhibit
assay
done
follow
confluent
monolay
cell
grown
plate
incub
compound
co
atmospher
h
subsequ
medium
remov
tcid
virus
ad
well
incub
h
cell
monolay
gentli
wash
pb
fresh
medium
ad
plate
plate
incub
humidifi
atmospher
co
cpe
observ
viru
neg
control
compar
cell
control
mtt
test
viral
inhibit
ratio
determin
csfv
replic
restrict
cell
cytoplasm
result
cytopath
effect
therefor
possibl
observ
directli
foci
viral
growth
due
fact
realtim
quantit
pcr
rtqpcr
use
sybr
green
develop
determin
copi
viru
suspens
rna
extract
cell
cultur
supernat
csfvinfect
cell
use
trizol
method
accord
manufactur
instruct
ambion
shanghai
china
synthesi
cdna
perform
random
prime
use
mmlv
revers
transcriptas
describ
previous
de
arc
et
al
pcr
primer
hclvfp
hclvrp
synthes
tianyi
huiyuan
wuhan
hubei
china
use
amplifi
fragment
conserv
genom
hog
cholera
viru
strain
hclv
sequenc
avail
genbank
reaction
mixtur
contain
steril
water
buffer
dntp
mixtur
mgcl
mmoll
primer
hclvfp
hclvrp
revers
transcript
product
ex
dna
polymeras
ex
taq
thermal
condit
set
follow
one
cycl
min
follow
cycl
final
extens
min
pcr
product
insert
vector
construct
recombin
plasmid
thclv
transform
e
coli
host
bacteria
increas
host
bacteria
recombin
plasmid
purifi
use
plasmid
miniprepar
kit
tiangen
kept
later
use
realtim
pcr
amplif
target
gene
fragment
use
reaction
mixtur
contain
sybr
premix
cdna
primer
steril
water
reaction
carri
biorad
real
time
pcr
hercul
ca
usa
condit
follow
one
cycl
min
follow
cycl
analyt
sensit
evalu
test
standard
plasmid
sequenti
ten
fold
dilut
depc
treat
water
determin
reproduc
realtim
pcr
standard
plasmid
dilut
respect
depc
treat
water
evalu
intraassay
variabl
dilut
analyz
triplic
measur
interassay
variabl
dilut
analyz
three
differ
run
perform
two
differ
oper
differ
day
coeffici
variat
cycl
threshold
ct
valu
within
block
among
block
use
mean
valu
block
determin
anticsfv
assay
done
dynam
follow
previou
method
mntc
compound
csfv
use
assay
cell
plate
preincub
csfv
h
subsequ
medium
remov
cell
wash
twice
pb
fresh
medium
contain
compound
ad
plate
incub
co
atmospher
cell
cultur
supernat
csfvinfect
cell
collect
h
h
h
h
h
h
h
h
respect
cell
control
viru
neg
control
set
simultan
rna
isol
cdna
synthesi
sampl
subject
rtqpcr
detect
copi
number
compar
growth
curv
whether
qdno
anticsfv
activ
could
judg
statist
analysi
perform
use
spss
softwar
experi
repeat
three
time
data
repres
mean
replic
sampl
independ
experi
express
mean
sd
student
ttest
oneway
anova
use
valu
p
consid
statist
signific
result
vitro
evalu
antifung
activ
qdno
shown
tabl
mic
qualiti
control
drug
amphotericin
b
ketoconazol
c
parapsilosi
c
albican
fell
within
rang
compar
result
previou
studi
mic
cya
cryptococcu
neoforman
determin
qct
activ
microsporum
cani
mic
result
suggest
qct
could
inhibit
growth
superfici
fungi
cya
inhibitori
activ
superfici
fungi
deep
fungi
deoxid
metabolit
qdno
tabl
ineffect
fungi
indic
presenc
two
noxid
group
quinoxalin
ring
necessari
antifung
activ
antimycoplasma
suscept
test
result
qdno
antimycoplasma
drug
shown
tabl
mic
control
drug
tylosin
enrofloxacin
gallisepticum
hyopneumonia
within
differ
previou
find
date
obtain
indic
effect
three
qdno
drug
mycoplasma
mic
mic
qct
gallisepticum
determin
metabolit
qdno
ineffect
mycoplasma
indic
presenc
two
noxid
group
ring
necessari
antimycoplasma
activ
mic
antimycoplasma
drug
show
good
activ
gallisepticum
tabl
shown
tabl
cya
meq
qct
combin
tetracyclin
tetracyclin
doxycyclin
addit
effect
gallisepticum
result
antituberculosi
activ
qdno
shown
tabl
mic
qualiti
control
drug
rifampicin
isoniazid
tuberculosi
within
differ
rang
previou
studi
three
qdno
drug
show
good
effect
bovi
tuberculosi
mic
qdno
metabolit
ineffect
tuberculosi
complex
confirm
find
report
presenc
two
noxid
group
quinoxalin
ring
necessari
antitubercular
activ
result
mic
seven
antituberculosi
drug
show
good
activ
tuberculosi
complex
tabl
seen
tabl
cya
meq
cytotox
assay
essenti
initi
phase
antivir
drug
develop
mntc
cc
valu
test
compound
list
tabl
observ
cya
meq
qct
exhibit
cytotox
metabolit
cell
cell
cell
except
test
compound
show
cc
valu
rang
mntc
rang
result
obtain
antiprrsv
antippv
antiibdv
assay
demonstr
qdno
metabolit
show
effect
virus
vitro
addit
file
control
drug
ribavirin
possess
good
inhibitori
activ
infect
inhibit
assay
virucid
assay
adsorpt
inhibit
assay
anticsfv
assay
plasmid
contain
bp
gene
fragment
hclv
use
fig
concentr
plasmid
dilut
equival
standard
curv
plot
copi
number
horizont
coordin
ct
valu
vertic
coordin
base
result
rtqpcr
standard
curv
linear
rang
r
reaction
effici
fig
limit
detect
rtqpcr
method
linear
rang
span
addit
file
dissoci
curv
analysi
perform
complet
pcr
confirm
tm
amplifi
templat
addit
file
amplif
plot
well
melt
curv
show
nonspecif
amplif
nonspecif
primer
dimer
amplif
highli
reproduc
coeffici
variat
within
run
intraassay
variabl
rang
interassay
variabl
rang
compar
growth
curv
observ
signific
chang
copi
csfv
blank
control
drugtreat
group
fig
indic
qdno
inhibitori
activ
csfv
antonio
cowork
first
report
synthesi
anticandida
activ
shown
qdno
derivati
without
substitut
mic
clinicalisol
c
albican
consist
result
tabl
base
report
result
qdno
gener
good
antifung
activ
report
qdno
mycoplasma
qdno
derivati
synthes
submit
antimycoplasma
assay
mycoplasma
homini
result
show
sever
compound
inhibit
growth
mycoplasma
concentr
mgml
base
result
qdno
may
better
antimycoplasma
activ
gallisepticum
hyopneumonia
tabl
report
antivir
activ
quinoxalin
focus
deriv
indoloquinoxalin
antivir
effect
indoloquinoxalin
depend
intercal
dna
helix
disturb
step
vital
viral
uncoat
qdno
redoxactiv
hypoxiaselect
dna
cleav
compoud
studi
neither
qdno
metabolit
show
antivir
activ
probabl
due
differ
chemic
structur
test
qdno
indoloquinoxalin
indol
group
might
import
antivir
activ
past
year
qdno
deriv
gradual
becom
research
hotspot
found
possess
good
activ
tuberculosi
one
five
lead
compound
seri
current
pursu
tuberculosi
antimicrobi
acquisit
coordin
facil
taacf
program
seri
qdno
deriv
quinoxalin
deriv
test
taacf
program
mani
compound
possess
good
antitubercular
activ
analog
even
found
activ
singledrugresist
strain
nonrepl
bacteria
studi
meq
show
antitubercular
activ
tuberculosi
mic
consist
previou
report
avail
inform
far
result
support
interest
devot
qdno
novel
class
antituberculosi
agent
shown
potenc
quinoxalin
make
valid
lead
synthes
new
compound
possess
better
activ
especi
activ
tuberculosi
applic
quantit
structureact
relationship
qsar
serv
ration
guid
design
qdno
deriv
help
resourc
tool
synthes
novel
antitubercular
candid
also
modifi
old
exist
quinoxalin
drug
synergist
addit
combin
two
agent
overcom
toxic
side
effect
associ
high
dose
singl
drug
counter
biolog
compens
allow
reduc
dosag
compound
access
contextspecif
multitarget
mechan
combin
cya
meq
qct
antibacteri
show
addit
indiffer
interact
fic
index
neither
antagon
synerg
qdnoantibacteri
combin
gallisepticum
tuberculosi
complex
observ
result
vitro
trial
provid
evid
cya
meq
qct
combin
antibacteri
could
produc
clinic
relev
addit
effect
pathogen
without
antagonist
interact
therefor
qdno
may
serv
promis
compound
futur
treatment
prevent
mycoplasm
tuberculosi
infect
studi
confirm
first
time
qdno
good
inhibitori
activ
mycobacterium
tuberculosi
complex
mycoplasma
may
reduc
threat
drug
resist
emerg
two
import
pathogen
effect
drug
combin
moreov
studi
develop
method
evalu
drug
csfv
vitro
provid
new
altern
screen
anticsfv
drug
studi
give
new
insight
applic
qdno
offer
way
promot
develop
anim
husbandri
fig
curv
viru
replic
cultur
qdno
main
metabolit
mean
sd
n
cell
incub
csfv
h
fresh
medium
contain
compound
cya
qct
meq
b
cy
c
ad
cell
cultur
supernat
csfvinfect
cell
collect
h
interv
rna
isol
cdna
synthesi
sampl
subject
realtim
pcr
detect
copi
number
logconcentr
yaxi
indic
denari
logarithm
copi
number
csfv
per
microlit
bk
blank
control
